Dr. Michael A. Gelfand, MD

Dr. Gelfand practices at Perelman Center For Advanced Medicine in Philadelphia, Pennsylvania.

Dr. Gelfand's NPI, 1861706525, was assigned on August 4, 2010. Dr. Gelfand graduated from Weill Cornell Medicine in 2010. Dr. Gelfand holds Pennsylvania license MD452895.

Dr. Gelfand's primary practice is Perelman Center for Advanced Medicine, at 3400 Civic Center Blvd Fl 2 Fl 2, Philadelphia, PA 19104. The practice phone is (215) 615-4949.

Dr. Gelfand's primary practice is Perelman Center For Advanced Medicine in Philadelphia, Pennsylvania. Dr. Gelfand is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Gelfand to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gelfand practices, 6 sites in all. Vendor and product names are available with a free account.

Epilepsy is Dr. Gelfand's primary specialty in the NPI Registry, under taxonomy code 2084E0001X. Dr. Gelfand is board certified in epilepsy by the American Board of Psychiatry and Neurology. Dr. Gelfand is licensed in Pennsylvania.

Dmand AI lists cerebrovascular disease, encephalopathy, epilepsy and seizures among the conditions Dr. Gelfand treats.

CMS data shows 360 Medicare services from Dr. Gelfand across 7 procedure codes in 2024, for 249 Medicare patients. Medicare paid $31,000 for them.

CMS counts 249 Medicare patients who saw Dr. Gelfand in 2024. The largest group is 65 to 74, with 97 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 37% are also on Medicaid. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gelfand's median patient age at 41, with 48% women.

In 2024, Dr. Gelfand wrote 1,669 Medicare Part D claims for 197 patients. 79% of them were for generic drugs. CMS names the drug for 1,525 of them, across 29 drugs with 11 or more claims each, at $1,052,226 in total drug cost. In 2023, CMS named 1,530 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Gelfand for performance year 2024, reported as part of a group. Dr. Gelfand accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gelfand as offering telehealth.

Dmand AI links 15 papers to Dr. Gelfand, published from 2010 to 2025. 2020 was the busiest year, with 4. The most frequent topics are Anticonvulsants, Electroencephalography and Epilepsy. Dr. Gelfand has published most often in Epilepsia. Dr. Gelfand's most frequent co-authors are Scott E. Kasner, MD, Selim Ramin Benbadis, MD and Andrew S. Blum, MD, PhD.

Dmand AI links Dr. Gelfand to 1 clinical trial. Conditions studied include Epilepsies, Partial and Seizures.

CMS Open Payments shows 69 general payments to Dr. Gelfand from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 88% of the total. UCB, Inc. paid the most, $40,910. It also lists 15 research payments totaling $3,059 from 2017 to 2020.

Dr. Gelfand graduated from Weill Cornell Medicine in 2010.

Dr. Gelfand is in network with 20 carriers, including Aetna, Elevance and HCSC. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.